Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3801239 | 0.95 | SMN1; SMN2 (0.44) | SMN1; SMN2KAT2BALDH1A1NPSR1KMT2A | |
| SCHEMBL3797761 | 0.91 | GNRHR (0.36) | SMN1; SMN2RAD52 | |
| SCHEMBL2938027 | 0.79 | HRH3 (0.46) | ALDH1A1KMT2AMAPT | |
| SCHEMBL2933683 | 0.75 | ACP1 (0.39) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3794972 | 0.73 | SMN1; SMN2 (0.47) | SMN1; SMN2KAT2BALDH1A1NPSR1KMT2A | |
| SCHEMBL2937283 | 0.72 | MAPT (0.44) | SMN1; SMN2ALDH1A1NPSR1KMT2AMAPT | |
| SCHEMBL17678158 | 0.68 | SMN1; SMN2 (0.57) | SMN1; SMN2KAT2BALDH1A1NPSR1KMT2A | |
| SCHEMBL4743774 | 0.68 | ALDH1A1 (0.67) | SMN1; SMN2KAT2BALDH1A1NPSR1KMT2A | |
| SCHEMBL4800824 | 0.67 | KCNH2 (0.42) | SMN1; SMN2NPSR1KMT2ARAD52MAPT | |
| SCHEMBL9725555 | 0.67 | MAPT (0.56) | SMN1; SMN2ALDH1A1NPSR1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267147-A1 | Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament | IPSEN PHARMA S.A.S. (FR) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267147-A1 | Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament | MC4R, MC1R, MC5R | SMN1; SMN2 3469/4885KAT2B 1766/4885ALDH1A1 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.